229 related articles for article (PubMed ID: 9540056)
1. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
[TBL] [Abstract][Full Text] [Related]
2. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence.
Hakin-Smith V; Battersby RD; Maltby EL; Timperley WR; Royds JA
Neuropathol Appl Neurobiol; 2001 Feb; 27(1):40-9. PubMed ID: 11299001
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
4. P53 overexpression and proliferative potential in malignant meningiomas.
Nagashima G; Aoyagi M; Yamamoto M; Yamamoto S; Wakimoto H; Ohno K; Yamamoto K; Hirakawa K
Acta Neurochir (Wien); 1999; 141(1):53-61; discussion 60-1. PubMed ID: 10071687
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
6. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
7. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
8. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of mdm2 and p53 and association with progesterone receptor expression in benign meningiomas.
Das A; Tan WL; Teo J; Smith DR
Neuropathology; 2002 Sep; 22(3):194-9. PubMed ID: 12416559
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
11. Pathological analyses of early recurrence and malignant transformation in meningiomas.
Arai H; Beppu T; Wada T; Yoshida Y; Kubo Y; Suzuki M; Ogawa A
Brain Tumor Pathol; 1998; 15(1):37-40. PubMed ID: 9879462
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
Abramovich CM; Prayson RA
Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
15. Expression of Ki-67 and p53 in meningiomas.
Pavelin S; Becic K; Forempoher G; Mrklic I; Pogorelic Z; Titlic M; Andelinovic S
Neoplasma; 2013; 60(5):480-5. PubMed ID: 23790165
[TBL] [Abstract][Full Text] [Related]
16. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas.
Matsuno A; Nagashima T; Matsuura R; Tanaka H; Hirakawa M; Murakami M; Tamura A; Kirino T
Am J Clin Pathol; 1996 Dec; 106(6):776-81. PubMed ID: 8980354
[TBL] [Abstract][Full Text] [Related]
17. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
18. Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation.
Amatya VJ; Takeshima Y; Inai K
Mod Pathol; 2004 Jun; 17(6):705-10. PubMed ID: 15073599
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.
Pykett MJ; Landers J; George DL
J Neurooncol; 1997 Mar; 32(1):39-44. PubMed ID: 9049861
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
